The mechanisms of action of the potent antiarrhythmic drug amiodarone are unknown. However, amiodarone and its abundant metabolite, desethylamiodarone, bear a striklng structural resemblance to thyroid hormones. In addition, certain cardiac electrophysiologic effects of amiodarone treatment are similar to those of hypothyroidism. These facts suggest that amiodarone or desethylamiodarone could be acting, in part, by blocking thyroid hormone action. Because thyroid hormones are known to act through nuclear receptor protems, the binding of amiodarone and desethylamiodarone was measured to nuclear extracts derived from human lymphocytes, bovine atrium and ventricle and rat liver.
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The capacity of increasing concentrations of amiodarone and desethylamiodarone nuclear extracts to block receptor binding of radiolabeled triiodothyronine (T3) in a standard in vitro competition assay was tested. Nuclear extracts demonstrated only minimal binding to Amiodarone is an important antiarrhythmic agent whose mechanism of action is not yet fully understood. Current information suggests that amiodarone may act through its influence on nuclear receptors for thyroid hormone in target tissues (I) . Amiodarone and its abundant metabolite, desethylamiodarone, are structurally similar to the physiologically active iodothyronines, thyroxine (Tot) and 3,5,3'-triiodo-Lthyronine (T 3 ) ( Fig . I ) . Furthermore, long-term amio-amiodarone. However, all receptor preparations had substantial affinities (J(o) for the desethyl analog: lymphocyte, 8.6 ILM; atrium, 35.0 ILM; ventricle, 26.9 p.M and liver, 8.6 p.M. Desethylamiodarone accumulates in very large quantities in parenchymatous organs during long-term amiodarone treatment. Taking its usual therapeutic serum level (about 4 p.M or 2.7 p.g/ml) as an estimate of intranuclear concentration, desethylamiodarone would partially saturate nuclear thyroid hormone receptors in several different tissues, including the heart, Thus, amiodarone treatment may exert some of its electrophysiologic effects by metabolic conversion to desethylamiodarone. This metabolite may then exclude thyroid hormone froin nuclear receptor sites within the myocardium.
(J Am Coli Cardiol 1987;9:872-6) darone therapy is associated with prolongation in duration of cardiac action potential and electrical refractoriness (2, 3) , changes that may figure significantly in its antiarrhythmic efficacy . These effects resemble electrophysiologic changes occurring with hypothyroidism (4) ; they are prevented by concomitant administration of thyroid hormone (2) . These considerations have led to the concept that amiodarone therap y may modulate the interaction of thyroid hormone and its receptors in myocardium and other tissues. However, no experimental data have been presented to evaluate a potential influence of amiodarone and its metabolites on binding of thyroid hormon e to tissue receptors . Such data may be valuable in clarifying the mechanism behind the metabolic alterations associated with long-term amiodarone therap y. We therefore examined the capacity of amiodarone and deseth ylamiodarone to compete for the binding of T J to specific nuclear thyroid hormone receptors in rat liver , bovine heart and human lymph ocyte s. Rat liver was utilized becau se nuclear thyroid hormone receptors from this tissue have been the protot ype in numerous studies of the binding properties of thyroid hormone analogs. Bovine heart provided an abundance of fresh tissue from each animal for studies of myocardial nuclear thyroid hormone receptors . Lymphocytes furnished the only readily accessible source for nuclear thyroid hormone receptors in humans.
Methods
Reagents. High specifi c activity ('~51 )3.5.3 ' -triiodo-Lthyronine (' 25 IT J • 1.200 JLCi /JLg) was obtained from New England Nuclear. Unlabeled triiodothyronine (T~) and thyroxine (T 4) were purchased from Sigma Chemical Company. Chromatographically pure reverse 1'. 1 was purchased from Calbiochem-Behring . The unlabeled thyroid hormones (T4. T3, reverse T3) were checked for purity by high performance liquid chromatography as described previously (5) . T 3 and reverse T 1 contained less than 0 .5% contaminants (measured as optical den sity at wavelength 01'280 nrn) and were used unpurified . Th yroxine intermittently contained trace amounts of 3 ,5-T 2 and T3 and was purified when necessary (6) .
Pure powdered amiodarone and desethylamiodarone were supplied by Sanofi Laboratories and were found to be homogeneous by high performance liquid chromatography (7) . Amiodarone and desethylamiodarone contained undetectable amounts of the opposite analog at detector sensitivities that could identify 0.1 % contaminant. High performance liqu id chromatography also confirined the solubility and stability of amiodarone and desethylamiodarone in dilute ethanol solutions. Stock solutions of amiodarone or desethylamiodarone, 10 mM in pure ethanol, were diluted directly into assay buffer just before use. Assay preparations containing various concentrations of either drug remained clear and showed no evidence of precipitation during the cour se of the experiments.
Receptor preparation. Solubilized nuclear thyroid hormone receptors from rat liver. bovine atrium and bovine .ventricle were prepared as described prev iously (6) . Briefly , 100 g of fresh tissue (rat liver, bovine ventricle or bovine atrial appendage) was homogenized in 300 ml of warm (37°C) 2.1 M sucrose solution containing 5.0 mM magnesium chloride and O. I mM phenylmethylsulfonylfluoride .
Nuclei were isolated from filtered homogenate by pelleting through cold 2 . 1 M sucrose (25, 000 x g for 2 h) . Nuclei were washed in buffer (30 mMTri s, pH 7 .6,2 mM calcium chloride , 1.1 mM magne sium chloride) containing 0 .5 % Triton X-100. then extracted in either 40 ml (liver) or 20 ml (atrium and ve ntricle) of buffer containing 0.2 M (NH 4hS0 4. The insoluble fraction was removed by centrifugation (50,000 x g for 2 h) and the supernatant fraction, containing thyroid hormone binding activity, was stored in liquid nitrogen . Chromatin extracts were also prepared from lymphocytes derived from euthyroid human donors as described prev iously (8) .
Hormone-binding studies. The relative recept or binding of each test compound was measured by binding site competition between 125IT.\ and different concentrations of each test compound: reverse T3 (30 nM to 10 p.M), amiodarone and desethylamiodarone (0 .3 JLM to 0.1 rTIM) and T J and T 4 (0 .1 nM to 30 nM). Hormone binding reactions contained 0.1 nM mlT~in a total reaction volume of 0 .5 ml. For saturation analy sis. bound hormone was separated from free hormone on Sephadex G-25 columns (2 .0 ml bed volum e ) as de scribed previou sly (6) . Binding site competition betw een 1251T 1 and nonradioactive T J or T 4 was not influenc ed by the presen ce of maximal concentrations of the solvent for amiodarone and desethylamiodarone (ethanol, I% in assay buffer) . 
Results
Binding to nuclear thyroid hormone receptors from rat liver (Table 1, are consistent with previous reports (6) . Desethylamiodarone demonstrated active competition for T 3 binding to the receptor but with a loweraffinity than T3, T4 or reverse T 3 • Amiodarone did not show any competition in the concentration range tested. Thus, the desethylated analog of amiodarone bound to the rat liver nuclear receptor (Kj, = 8.6 J-LM) whereas amiodarone did not bind. Binding to human lymphocyte chromatin extracts ( Table I , Fig: 2B ). Consistent with previous findings, we observed abundant high affinity T 3 (K o = 1.2 oM) and T 4 binding (K o = 0.8 oM ). Reverse T) had a higher affinity in this mixed binding system than in rat liver (Kj,estimated: 0.9 oM ). Desethylamiodarone again showed active binding to this mixed receptor system (K o = 8.6 J-LM. Amiodarone also showed modest displacement of 125IT3, a result that was not consistent with the findings in rat liver. However, the apparent affinity of amiodarone for nuclear thyroid hormone receptor was much less than that of desethylamiodarone or any of the thyroid hormones. It is improbable that this observed amiodarone binding was due to contamination of the amiodarone with the desethylated analog because nuclear thyroid hormone receptors derived from rat liver did not show a similar amiodarone displacement and our liquid chromatographic studies measuring the purity of the crystalline compounds indicated no contamination of the amiodarone with desethylamiodarone. Binding to nuclear thyroid hormone receptors from bovine atrium and ventricle (Table I, Fig. 2C and 2D ). Relative to the ventricle, atrium contained four to five times as much T 3 binding activity on a tissue wet-weight basis. For atrium, the order and affi nities of hormone binding were very similar to values obtained from rat liver ( where C", = molar concentration of competitor at 50% inhibition of T3 binding KilTJ is the K n of T, binding; 12SIT, = the molar concentration of the radiolabeled T, (0. 1 nM in thesestudies). t K n for amiodarone binding to receptors from human lymphocytes. DA = desethylarniodarone.
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Although material obtained from the ventricle showed less T, binding activity and lower affinity binding (T, K IJ = 10.1 nM; T 4 K D = 79 nM; reverse T, K n = 3.3 J.LM ) than the atrium, the order of hormone preference was the same in ventricle, atrium and rat liver. As in the atrium. desethylamiodarone showed active receptor binding (K D = 26.9 J.LM) ; amiodarone exhibited a small amount of displacement.
Discussion
Desethylamiodarone competition for thyroid hormone receptors. Our results demonstrate that desethylamiodarone has a substantial capacity to compete for thyroid hormone binding to nuclear thyroid hormone receptors derived from three different tissues in three different species. including humans. In general. this capability is not shared by the parent compound, amiodarone, although some weak competitive binding is noted in human lymphocytes (Fig.  2B ). This capacity suggests that desethylamiodarone may be able to influencemetabolic processes governed by thyroid hormone in a variety of tissues. Desethylamiodarone has a much lower affinity for nuclear thyroid hormone receptors than triiodothyronine (T,) or thyroxine (T 4 ) (Table J) . However, very large amounts of desethylamiodarone accumulate in parenchymatous organs of treated subjects (up to 6.500 rng/kg in human liver) (9) . Steady state blood concentrations of desethylamiodarone in patients on long-term amiodarone therapy approximate 4 J.LM (2.7 J.Lg/ml) (10) . If similar concentrations appear in cell nuclei, our data suggest that partial saturation of nuclear thyroid hormone receptors by desethylamiodarone is a distinct possibility. Thus. desethylamiodarone competition for thyroid hormone receptors may be signifi cant in the clinical use of this drug. both as a potential source of beneficial antiarrhythmic action, and as a factor in genesis of side effects in the many organ systems infl uenced by amiodarone treatment.
In addition to the binding properties of desethylamiodarone, our findings also demonstrate an even higher affinity of nuclear thyroid hormone receptors for reverse T,. Be-cause long-term amiodarone treatment results in a two-to fourfold rise in serum reverse T, levels (I), greater reverse T, occupancy of nuclear thyroid hormone receptor sites is a possible outcome of this therapy. The metabolic consequences of such a change are, at present. unknown. However. higher reverse T J levels could also act, possibly in concert with desethylamiodaronc, to displace thyroid hormone from its nuclear receptor and thereby contribute to a hypothyroid state within the heart or other tissues.
Role of blockade of thyroid hormone receptors in antiarrhythmic effects of amiodarone. Thyroid hormone levels clearly modulate myocardial repolarization. Isolated myocardium from thyroidectomized rabbits exhibits prolongation in the plateau phase of the action potential (4). Singh and Vaughan Williams (2) demonstrated that longterm amiodarone therapy produces repolarization delay similar to that caused by thyroidectomy. The repolarization changes induced by amiodarone can be prevented by concomitant thyroid hormone treatment (2) . More recently, Singh and Nademanee ( I) suggested that amiodarone therapy may influence cardiac muscle. in part. by blocking the actions of T, on nuclear thyroid hormone receptors. Our findings provide explicit experimental support for this concept by demonstrating a potential for blockade of nuclear thyroid hormone receptors in heart and other tissues during amiodarone therapy and by identifying a specific molecular species most likely responsible for this blockade. Transformation of amiodarone to desethylamiodarone and subsequent blockade induced by this metabolite may explain the early electrophysiologic results.
This postulated action of desethylamiodarone is consonant with present knowledge of the pharmacokinetic and pharmacodynamic aspects of amiodarone therapy in man. Thus, the long delay in onset of maximal antiarrhythmic efficacy of oral therapy and the relatively modest effects on repolarization with intravenous dosing despite equivalent blood and tissue levels of amiodarone may be explained by a requirement to convert amiodarone to desethylamiodarone, accumulate large intracellular stores of desethylamiodarone and await the relatively slow changes that would be expected with blockade of nuclear thyroid hormone receptors.
If desethylamiodarone competition for T, and T4 binding to nuclear thyroid hormone receptors is responsible, in part, for certain cardiac effects of amiodarone therapy, then desethylamiodarone must occupy the receptor site without activation. Such a blocking effect would be unique among various substances known to interact with nuclear thyroid receptors. In the past, an extensive survey of thyroid hormone analogs failed to identify any compound with receptor antagonist properties (10) .
If blockade of nuclear thyroid receptors is an important mediator of the cardiac actions of amiodarone therapy, this leaves unexplained the fact that effective amiodarone therapy is not uniformly accompanied by clinically overt generalized hypothyroidism. Although hypothyroidism develops in an appreciable number of patients receiving amiodarone, such patients generally have reduced levels of plasma T, and T 4 , an effect usually ascribed to an unusual metabolic response to the abnormal iodide load released with metabolic breakdown of amiodarone and desethylamiodarone (I, II). Current results offer no suggestion of myocardial selectivity for desethylarniodarone, because this substance appears able to bind nuclear thyroid hormone receptor sites with a similar affinity in all tissues studied (Table I) . These results do suggest that receptor affinity for T, is distinctly lower in the ventricles. This could permit desethylamiodarone to compete with T, more effectively in the ventricles than in other tissues. Such an explanation would not apply to the atria, which exhibit a clinical sensitivity to antiarrhythmic actions of amiodarone therapy exceeding that of the ventricles.
Therapeutic implications of the study. Caution must be used in interpreting our results. Relative concentrations of desethylamiodarone, arniodarone, reverse T" T, and T 4 in the vicinity of nuclear thyroid hormone receptors during long-term amiodarone therapy is unknown. In addition, the relation between nuclear thyroid hormone receptors and electrical functioning of the myocardium is uncertain. Other thyroid hormone receptors (for example, those on plasma membrane) may also be important in mediating thyroid hormone action on electrical activity. Ultimate determination of the capacity of amiodarone and desethylamiodarone to influence thyroid hormone action in the heart and other tissues must rely on measurement of metabolic indexes. Certain cardiac electrophysiologic effects of amiodarone therapy have no apparent connection with blockade of nuclear thyroid hormone receptors, for example, blockade of inactivated sodium channels (12, 13) . Moreover, the relation of potential thyroid-mediated changes (delayed repolarization and prolonged refractoriness) and antiarrhythmic efficacy has not been fully delineated.
The electrophysiologic and clinical effects of long-term treatment with independently administered desethylamiodarone are unknown. Electrophysiologic studies to date have focused on results of short-term administration of desethylamiodarone (14) , at time points before any likely influence resulting from inhibition of nuclear thyroid hormone receptors. Despite this multitude of uncertainties, our results suggest that further exploration of nuclear thyroid hormone receptor blockade may elucidate important aspects of antiarrhythmic efficacy and other consequences of amiodarone therapy.
